17,261 trials
Metastatic Pancreatic Adenocarcinoma · Stage III Pancreatic Cancer AJCC v6 and v7 · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 2; 2 Participants
Treatment Resistant Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3 — -12; -8.9; -6.8 units on a scale — p=<0.05
Prostate Cancer
Primary: Objective Response Rate (ORR) Cohorts B and C Per BICR — 12.5; 20.0 Percent of Participants
Fallopian Tube Cancer · Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Overall Response — 1; 1 Participants
Cognitive Impairment · Malignant Neoplasm
Primary: Effects of Ibuprofen on Alleviating Chemotherapy-related Cognitive Impairment — 89.98; 91.08; 105.54; 107.75 score on a scale — p=0.7917
Postoperative Nausea and Vomiting (PONV)
Primary: Percentage of Participants With Complete Response in the Immediate Postoperative Period — 48.8; 71.8 percentage of participants
Atopic Dermatitis
Primary: Nemolizumab Serum Concentrations at Week 1-2 — 6478.8 nanogram per milliliter (ng/mL)
Hearing Loss, Sensorineural · Noise Induced Hearing Loss · Sudden Hearing Loss
Primary: Word Recognition in Quiet — 14.7; 11.1 Percent of subjects — p=0.525
Amyotrophic Lateral Sclerosis
Primary: Pharmacodynamic Biomarkers: MCP-1 On-treatment Period Variation — 4.6; 2.2 pg/ml — p=0.6346
Malignant Neoplasm · Oral Pain · Stomatitis
Primary: Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool — 1.69; 5.2; 4.54; 5.15…
Ovarian Neoplasm
Primary: Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 17.9 Percentage of participants
HIV · Cardiovascular Disease
Primary: Change in CD4 Count From Baseline to Follow-up — -0.085; -0.024; -0.020; -0.090 log cells per mm^3
Metabolic Syndrome
Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 8; 16; 20 participants